```html

Tuberculous Meningitis – A Complete Patient Guide

Overview

Tuberculous meningitis (TBM) is a severe form of meningitis caused by the bacterium Mycobacterium tuberculosis that infects the membranes (meninges) surrounding the brain and spinal cord. It accounts for approximately 1–5 % of all TB cases but carries a disproportionately high mortality and disability rate, especially in children and immunocompromised adults.

Although TB is a global disease, TBM is most common in regions with high TB prevalence, such as South‑East Asia, sub‑Saharan Africa, and parts of Eastern Europe. In the United States, the Centers for Disease Control and Prevention (CDC) report roughly 200–300 new TBM cases each year, representing less than 1 % of all tuberculosis diagnoses.

Anyone infected with TB can develop TBM, but the risk is highest in:

• Infants and young children (especially < 2 years)
• People living with HIV or other immunosuppressive conditions
• Individuals with a recent or untreated pulmonary or extrapulmonary TB infection
• People with malnutrition or chronic illnesses (diabetes, renal failure)

Symptoms

TBM typically has a sub‑acute onset; symptoms develop slowly over days to weeks, which can delay diagnosis. The classic triad—headache, fever, and neck stiffness—may be present, but many patients exhibit additional neurological signs.

General symptoms

• Persistent headache – often described as “worst headache of my life,” can be frontal or occipital.
• Fever – low‑grade to high, usually continuous and may not respond to antipyretics.
• Neck stiffness – resistance to passive neck flexion, a hallmark of meningitis.
• Fatigue and malaise – profound tiredness that interferes with daily activities.
• Loss of appetite & weight loss – common in systemic TB infection.

Neurological symptoms

• Altered mental status – confusion, lethargy, or coma in severe cases.
• Photophobia – sensitivity to light.
• Vomiting – often non‑bloody and may be triggered by headache.
• Seizures – generalized or focal; occur in up to 30 % of patients.
• Focal neurologic deficits – weakness, cranial nerve palsies (e.g., III, VI, VII), or ataxia.
• Hydrocephalus signs – enlarged head circumference in infants, papilledema, or gait disturbances.

Pediatric‑specific clues

• Irritability or inconsolable crying
• Bulging fontanelle (soft spot) in infants
• Regression of developmental milestones

Causes and Risk Factors

TBM results from the spread of M. tuberculosis to the central nervous system (CNS). Two main pathways are recognized:

1. Hematogenous spread – bacteria disseminate from a primary lung focus (or other extrapulmonary site) via the bloodstream and seed the meninges.
2. Direct extension – less common, occurs from adjacent infected structures such as a vertebral (Pott’s) disease or a ruptured brain tuberculoma.

Key risk factors

• HIV infection – immune suppression raises the risk of CNS TB by 10–20 times (WHO, 2022).
• Recent close contact with an active TB case – especially in crowded living conditions.
• Age – children <2 years and adults >65 years have weaker cell‑mediated immunity.
• Malnutrition – protein‑calorie deficiency impairs granuloma formation.
• Immunosuppressive therapy – corticosteroids, TNF‑α inhibitors, chemotherapy.
• Diabetes mellitus – increases susceptibility to TB infection overall.

Diagnosis

Because TBM mimics other forms of meningitis, a high index of suspicion is essential. Diagnosis combines clinical assessment, imaging, and laboratory testing.

1. Lumbar Puncture (Spinal Tap)

• Cerebrospinal fluid (CSF) analysis – typical findings: opening pressure >180 mm H₂O, clear or slightly turbid fluid, protein 100–500 mg/dL (elevated), glucose <40 mg/dL or CSF/plasma ratio <0.5, lymphocytic predominance (but early TBM may be neutrophilic).
• Acid‑fast bacilli (AFB) smear – low sensitivity (10‑20 %).
• Culture – gold standard but takes 4–8 weeks.
• Polymerase Chain Reaction (PCR)/GeneXpert MTB/RIF – rapid (hours), sensitivity 60‑80 % in CSF, also detects rifampicin resistance.
• CSF adenosine deaminase (ADA) – elevated (>10 U/L) supports TBM in high‑prevalence settings.

2. Neuroimaging

• CT scan (non‑contrast) – quickly identifies hydrocephalus, basal meningeal enhancement, or infarcts.
• MRI with contrast – more sensitive; shows basal exudates, tuberculomas, and cerebral edema.
• Magnetic Resonance Angiography (MRA) – evaluates vasculitic infarcts, a frequent complication.

3. Additional Tests

• Chest X‑ray or CT – looks for active pulmonary TB, present in ~50 % of TBM cases.
• Interferon‑γ Release Assays (IGRA) or Tuberculin Skin Test – indicate prior TB infection but cannot confirm CNS disease.
• Blood cultures – rarely positive but may identify disseminated TB.

Diagnostic criteria

World Health Organization (WHO) and American Thoracic Society guidelines categorize TBM as “definite,” “probable,” or “possible” based on a scoring system that weighs clinical, CSF, imaging, and microbiologic data.

Treatment Options

Effective therapy requires prompt, multi‑drug antitubercular treatment (ATT) combined with adjunctive measures to reduce inflammation and manage complications.

1. Antitubercular Medications

Standard initial regimen (2‑month intensive phase) for adults and children:

• Isoniazid (H) – 10–15 mg/kg daily (max 300 mg)
• Rifampicin (R) – 10–15 mg/kg daily (max 600 mg)
• Pyrazinamide (Z) – 30–40 mg/kg daily
• Ethambutol (E) – 15–20 mg/kg daily
• Often an additional fluoroquinolone (e.g., levofloxacin 15–20 mg/kg) is added for CNS penetration.

After the intensive phase, a continuation phase (7–10 months) of isoniazid + rifampicin is given. Total treatment duration is usually 9–12 months, longer than pulmonary TB because of poor drug penetration into the CSF.

Key points:

• All drugs must be given in directly observed therapy (DOT) to ensure adherence.
• Therapeutic drug monitoring (TDM) is advisable, especially in children, HIV patients, and those on interacting medications.
• Drug‑resistant TBM (MDR/XDR) requires second‑line agents (e.g., linezolid, bedaquiline) and specialist input.

2. Adjunctive Corticosteroids

Prednisone or dexamethasone (0.4 mg/kg IV loading then taper) reduces mortality by ~30 % in adults and improves neurological outcomes in children (MRC 1994 trial). Steroids are standard of care unless contraindicated.

3. Management of Hydrocephalus

• External ventricular drain (EVD) – temporary relief of acute raised intracranial pressure.
• Ventriculoperitoneal (VP) shunt – permanent diversion for chronic communicating hydrocephalus.

4. Anticonvulsants

Seizures occur in up to one‑third of patients; levetiracetam or phenytoin is commonly used.

5. Supportive Care & Lifestyle Adjustments

• Adequate nutrition (high‑protein diet) to support immune recovery.
• Hydration and electrolyte balance, especially if on high-dose steroids.
• Physical and occupational therapy to address motor deficits.
• Avoid smoking and alcohol, which impair TB treatment efficacy.

Living with Tuberculous Meningitis

Recovery can be prolonged and may involve residual neurologic deficits. Below are practical tips for patients and caregivers.

Daily Management

• Medication adherence – use pill organizers, set alarms, and attend all DOT appointments.
• Monitor side effects – visual changes (ethambutol), liver dysfunction (isoniazid, rifampicin, pyrazinamide), peripheral neuropathy (isoniazid – give pyridoxine 25 mg daily).
• Regular follow‑up – neurologist, infectious disease specialist, and primary care visits every 2–4 weeks during intensive phase, then monthly.
• Rehabilitation – engage in physiotherapy early to prevent contractures and improve gait.
• Vaccinations – stay up‑to‑date, especially pneumococcal and influenza vaccines, to reduce secondary infections.
• Psychosocial support – counseling, support groups, and educational resources help cope with anxiety or depression.

Returning to Work/School

Most patients can resume light activities after 2–3 months if neurologically stable and after completing the intensive phase. Discuss a phased return with your physician; accommodations for fatigue and possible cognitive deficits may be necessary.

Prevention

Preventing TBM begins with preventing TB infection and ensuring early treatment of any TB disease.

• BCG vaccination – offers significant protection against severe TB forms, including meningitis, in children; recommended in high‑burden countries (WHO, 2023).
• Identify and treat latent TB infection (LTBI) – especially in close contacts of active cases, HIV‑positive individuals, and those on immunosuppressants. Regimens include 3 months of weekly isoniazid‑rifapentine (3HP) or 4 months of daily isoniazid (4HR).
• Infection control – adequate ventilation, UV germicidal irradiation in high‑risk settings (e.g., hospitals, prisons).
• Adhere to TB treatment – incomplete therapy leads to drug resistance and CNS dissemination.
• Healthy lifestyle – balanced diet, regular exercise, avoidance of tobacco and excess alcohol to keep immunity robust.

Complications

If TBM is delayed or inadequately treated, serious complications may develop:

• Hydrocephalus – in up to 50 % of patients; may require permanent shunting.
• Cerebral infarcts – basal‐artery vasculitis leads to stroke, often resulting in hemiparesis or visual field loss.
• Seizure disorder – can become chronic, requiring long‑term anticonvulsants.
• Hearing loss – from meningeal inflammation or drug toxicity (streptomycin).
• Cognitive and psychiatric sequelae – memory impairment, attention deficits, depression.
• Long‑term motor disability – spasticity, ataxia, or permanent paralysis.
• Mortality – 10‑30 % in adults and up to 50 % in children in low‑resource settings (Cochrane Review 2021).

When to Seek Emergency Care

References

• World Health Organization. Global Tuberculosis Report 2023. PDF.
• Centers for Disease Control and Prevention. Tuberculosis (TB) – Fact Sheet. CDC.
• British Medical Journal. “Tuberculous meningitis: A review of clinical presentation and management.” BMJ 2022; 378:e069789.
• Mayo Clinic. “Tuberculous meningitis.” Mayo Clinic.
• Cochrane Database of Systematic Reviews. “Adjunctive corticosteroids for tuberculous meningitis.” 2021.
• Cleveland Clinic. “Hydrocephalus and Tuberculous Meningitis.” Cleveland Clinic.
• National Institutes of Health. “Guidelines for Treatment of Drug‑Resistant Tuberculosis.” NIH.

```